NCT03322657View on ClinicalTrials.gov

Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular

PHASE4CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

November 14, 2017

Primary Completion Date

December 31, 2020

Study Completion Date

February 1, 2021

Conditions
Neuromuscular BlockadeAnesthesia
Interventions
DRUG

Neostigmine

Neostigmine injection

DRUG

Glycopyrrolate

Glycopyrrolate injection

DRUG

Sugammadex

Sugammadex injection

Trial Locations (1)

44195

Cleveland Clinic, Cleveland

All Listed Sponsors
lead

The Cleveland Clinic

OTHER

NCT03322657 - Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular | Biotech Hunter | Biotech Hunter